Our breakthrough, proprietary technology platform engineered to enhance drug absorption
End-to-end, in-house control of formulation, development, and manufacturing capabilities
Our proprietary cannabinoid composition for the management of pain and inflammation
Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials
Learn more about cannabidiol from the medical community and regulators
We are modernizing the way medicines are taken
Experts in drug development and delivery, manufacturing, and commercialization
Recent media coverage regarding Orcosa
Company news and announcements
June 30, 2025 – EWING, N.J. – Orcosa Inc. (“Orcosa” or the “Company”), a clinical-stage life-sciences company improving patient outcomes through its next-generation drug-delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced the appointment of Kevin Kaplan, M.D., FAAOS, as Chief Medical Officer. In this role, Dr. Kaplan will direct clinical development, regulatory strategy and medical affairs as the Company advances its pipeline of therapeutics built on the RITe™ Platform.
“We are thrilled to welcome Dr. Kaplan to our leadership team,” said Bryan Ridall, President & Chief Executive Officer of Orcosa. “Kevin has spent nearly two decades operating at the highest levels of sports medicine, where safety, speed and performance are paramount. His hands-on clinical expertise, coupled with a deep understanding of musculoskeletal and pain-management needs, will be invaluable as we position our lead non-opioid pain program for late-stage development and expand the RITe™ Platform into new therapeutic areas.”
Dr. Kaplan stated “Throughout my career I have sought solutions that let athletes and patients recover faster without compromising safety. I believe Orcosa’s technology offers a fundamentally better way to deliver medicines, and I am excited to help translate that promise into rigorous clinical evidence and, ultimately, real-world impact.”
About Kevin Kaplan, M.D.Dr. Kaplan brings two decades of elite sports-medicine experience to Orcosa. He has served 16 seasons as a physician for the Jacksonville Jaguars with the last 12 years as Head Team Physician, overseeing player health and supporting a number of local and regional teams in the Southeast. Dr. Kaplan earned a B.S. in cell & molecular Biology from Tulane University (summa cum laude) and an M.D. from New York University School of Medicine (Alpha Omega Alpha). He completed his orthopaedic residency at NYU Langone – serving as Executive Chief Resident – and a sports medicine fellowship at the Kerlan-Jobe Orthopaedic Clinic, where he assisted the 2009 NBA Champion L.A. Lakers. Dr. Kaplan is a board-certified surgeon with a subspecialty designation in sports medicine and is a Fellow of both the American Orthopaedic Society for Sports Medicine and the Arthroscopy Association of North America and has authored more than 20 peer-reviewed publications.
About Orcosa Inc.
Orcosa Inc. is a life-sciences company modernizing the way medicines are taken and improving patient outcomes through its proprietary therapeutic delivery technology, the Rapid Infusion Technology (RITe™) Platform. Orcosa is the inventor, developer and exclusive owner of the RITe™ Platform, a fast-acting, easy-to-take tablet engineered to enhance drug absorption. Orcosa’s lead program, ORAVEXX™, is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and has the potential to provide a safe, alternative treatment option to opioids and NSAIDs. The Company is currently supporting clinical trials at leading American research institutions to evaluate the safety and effectiveness of ORAVEXX™ for pain management. For more information, please visit www.orcosa.com.
Forward-Looking Statements
Certain statements made herein constitute “forward-looking statements.” These forward-looking statements include, but are not limited to, the development of ORAVEXX™ and the RITe™ Platform. These statements are based on the current expectations of Orcosa and are not predictions of actual performance. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Orcosa to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Media Contact:
media@orcosa.com
Investor Contact:
IR@orcosa.com